Does Semax increase BDNF?
Semax consistently and significantly increases BDNF expression and protein levels in multiple brain areas, experimental models, and via various administration routes. This makes the increase in BDNF one of the best-documented and most reproducible mechanisms underlying the neuroprotective and pro-cognitive effects of this peptide.
BDNF, or brain-derived neurotrophic factor, is a protein produced by the brain to keep nerve cells in good condition, support their growth, strengthen the connections between them, and protect them from damage and disease. You can think of it as the brain's internal repair and maintenance protein.
Evidence for Semax's BDNF-increasing action includes laboratory cell cultures, living animal brain tissue, and clinical studies on humans – creating one of the stronger chains of evidence available for the mechanism of action of any synthetic peptide. The magnitude of BDNF increases, which brain areas are affected, and how this changes over time have been studied in detail – through over a decade of research. Further consequences, such as the activation of the BDNF receptor called TrkB, improvements in synaptic plasticity, and measurable cognitive benefits, have been directly linked to these neurotrophic changes in numerous studies.
How much does Semax increase BDNF? Evidence from animal studies
The magnitude of BDNF increases induced by Semax depends on the tissue type, brain region, and measured time point. However, the fold-change increases documented in animal studies are significant and pharmacologically relevant.
In rat glial cell cultures – laboratory-grown samples of supporting brain cells taken from the basal forebrain of newborns – Semax induced an 8-fold increase in BDNF mRNA levels within just 30 minutes of administration. mRNA is the molecular instruction that cells use to produce proteins. An 8-fold increase means that the instructions for producing BDNF rose to eight times the normal level. This is one of the fastest and most pronounced effects of neurotrophin gene activation ever documented for any synthetic regulatory peptide.
In living rat hippocampal tissue – the hippocampus being the brain area most associated with learning and memory – a single intranasal dose of Semax at 50 micrograms per kilogram of body weight caused a peak 1.4-fold increase in BDNF protein levels. It also induced a 1.6-fold increase in TrkB tyrosine phosphorylation – a chemical change indicating that the BDNF receptor was activated and actively delivering BDNF effects intracellularly – alongside a 3-fold increase in BDNF mRNA and a 2-fold increase in TrkB mRNA [2]. The molecular changes were accompanied by a measurable improvement in conditioned avoidance learning – a standard behavioural test assessing memory and learning ability in animals – directly linking molecular changes to actual functional outcomes [2].
Studies tracking BDNF gene activity at multiple time points revealed a more complex and dynamic picture. In the rat hippocampus, BDNF mRNA levels briefly decreased 20 minutes after administration, then significantly increased after 90 minutes. In the frontal cortex – a brain region responsible for decision-making and complex thinking – expression increased early and followed a different temporal pattern. In the retina, a significant increase in BDNF expression was specifically observed at the 90-minute mark [3]. BDNF mRNA levels in the hippocampus peaked at around 90 minutes and returned close to baseline values after approximately 8 hours [4]. However, the downstream effects triggered by TrkB receptor activation last considerably longer, via intracellular signalling processes that outlive the BDNF surge itself.
The study, which tracked the activity of BDNF and NGF genes at six time points – 20 minutes, 40 minutes, 90 minutes, 3 hours, 8 hours, and 24 hours – confirmed that the neurotrophin response to Semax is not a simple, constant increase. It is a dynamic, bidirectional regulation that differs between brain areas and between the two neurotrophin genes [3].
In a rat stroke model – where a blood vessel supplying the brain was permanently occluded to mimic ischemic stroke-induced damage – Semax enhanced the activity of the BDNF gene and its receptor TrkC 3 hours after occlusion, and the activity of the NGF gene at 24 and 72 hours [5]. This timeline of neurotrophin gene activation was described as selective for the ischemic context – Semax's effect on neurotrophin gene activity was more pronounced and consistently elicited in stroke-affected animals than in healthy ones. This suggests that Semax specifically enhances the brain's natural neurotrophin response to injury, rather than simply inducing a uniform, context-independent effect [5].
In our Alzheimer's disease model, both Semax and a related derivative improved cognitive function in behavioural tests and reduced the number of amyloid plaques – abnormal protein deposits that accumulate in the brain in Alzheimer's disease – in the cortex and hippocampus [6]. These effects are consistent with BDNF-mediated neuroprotection, although the study did not directly measure BDNF levels in this model. In a mouse model of Parkinson's disease using the neurotoxin MPTP – which destroys dopamine-producing neurons in a manner mimicking Parkinson's disease – Semax administered before the neurotoxin caused a slight but reliable increase in dopamine concentrations in the striatum. The authors interpreted this as evidence that Semax acts primarily by stimulating the brain's own production of neurotrophic factors, rather than as a direct antioxidant [7], further supporting the induction of neurotrophic factors as the primary mechanism of brain protection.
Does Semax increase BDNF in humans?
Semax increases plasma BDNF levels in human patients following ischaemic stroke – this being stroke caused by a blocked blood vessel cutting off oxygen supply to part of the brain. This constitutes the most direct clinical evidence that the increase in neurotrophins observed in animals also occurs in humans.
In a study of 110 patients following an ischaemic stroke, divided into early and late rehabilitation groups, the administration of Semax – irrespective of the timing of rehabilitation initiation – significantly increased plasma BDNF levels, which remained elevated throughout the observation period [8]. Plasma BDNF refers to BDNF measured in the liquid component of blood. In patients who did not receive Semax, high BDNF levels were associated with early rehabilitation initiation. Semax, however, independently elevated BDNF regardless of rehabilitation timing [8].
Crucially, elevated BDNF levels were positively correlated with improvements on the Barthel scale – a standard clinical tool measuring an individual's ability to perform daily activities such as bathing, dressing, and ambulation independently – and faster recovery of motor functions [8]. This establishes a direct clinical link between Semax-induced BDNF increase and significant, real-world functional recovery in human patients.
A previous clinical trial of Semax in 30 patients with acute ischaemic stroke also demonstrated neurological improvement and restoration of impaired functions, which researchers partly attributed to neuroprotective mechanisms mediated by neurotrophins characterised in parallel animal studies [9]. While plasma BDNF is an indirect measure of BDNF activity within the brain itself, the correlation between its increase and functional recovery outcomes provides significant clinical validation for the BDNF mechanism identified in preclinical studies.
How does Semax affect BDNF in the hippocampus?
Semax influences BDNF in the hippocampus via a biphasic, time-dependent gene regulation pattern, ultimately resulting in increased BDNF protein levels and enhanced TrkB receptor activation. As described above, a single intranasal dose of Semax induced a transient early decrease in hippocampal BDNF mRNA at 20 minutes, followed by a significant increase at 90 minutes, with the overall net effect being approximately a 1.4-fold increase in hippocampal BDNF protein at its peak [2], [3].
The hippocampus-specific regulation of BDNF is particularly significant, given the crucial role of this brain region in learning, memory consolidation, spatial navigation – the ability to orient and move within space – and stress regulation. Semax has demonstrated beneficial effects in all these areas. In studies measuring BDNF levels in the hippocampal tissue of mice with different cognitive profiles, Semax specifically increased BDNF levels in the hippocampus of mice that initially showed low cognitive performance, without altering BDNF levels in mice that performed well [10]. This suggests that Semax's BDNF-boosting effect operates preferentially under conditions of relative deficiency – meaning it has the greatest impact when BDNF levels are already low – which has important implications for understanding when and in whom Semax is most likely to provide significant cognitive benefits.
Does Semax increase NGF?
Semax increases the expression of nerve growth factor (NGF) – a protein crucial for the survival and maintenance of nerve cells, particularly in brain areas associated with memory and attention. The effects have been documented in many brain areas and experimental models, although the magnitude and duration of NGF increases differ from those concerning BDNF and vary significantly depending on the brain area and the measured time point.
In rat glial cell cultures from the basal forebrain, Semax induced a 5-fold increase in NGF mRNA within 30 minutes of administration, with this effect occurring concurrently with a more dramatic 8-fold increase in BDNF at the same time point [1]. In live rat brain tissue after nasal administration of Semax, NGF gene activity increased in the hippocampus at the 90-minute point. However, in the frontal cortex, NGF expression showed an early decrease before returning to normal levels [3]. This regionally distinct NGF response – an increase in the hippocampus versus an early decrease in the frontal cortex – reflects the complex, regionally specific manner in which Semax modulates neurotrophin systems and highlights the importance of analysing effects with respect to specific brain areas, rather than drawing broad, generalised conclusions.
Which studies show that Semax increases NGF expression?
The most detailed characterisation of NGF changes induced by Semax has been provided by studies tracking gene activity at multiple time points and in multiple brain areas simultaneously. The study by Shadrin et al. analysing the temporal dynamics of both NGF and BDNF revealed that retinal NGF activity remained relatively stable in the early period after administration, before eventually showing an increase, whilst hippocampal NGF showed a similar biphasic pattern to BDNF [3].
In the context of cerebral ischaemia, Semax enhanced NGF gene activity 24 and 72 hours after permanent middle cerebral artery occlusion [5]. This delayed NGF increase complemented the earlier BDNF response, together providing a sustained neurotrophic support signal during the critical window of post-stroke recovery. The fact that BDNF responds earlier and more dramatically than NGF may reflect different intrinsic regulatory mechanisms controlling each gene and potentially different functions that the two neurotrophins perform in acute versus long-term brain protection.
In the basal forebrain of rats – the main source of acetylcholine-producing neurons that project to the hippocampus and cortex – intranasal Semax at a dose of 50 micrograms per kilogram body weight induced measurable increases in BDNF protein levels 3 hours after administration [11]. Basal forebrain cholinergic neurons are critically dependent on NGF for their survival. These are also the neurons most affected in Alzheimer's disease. The effect of Semax in increasing NGF in this area is therefore particularly significant for its potential procognitive and anti-dementia properties.
Jak Semax działa na regenerację nerwów?
Nerve regeneration is a process where damaged nerve cells repair themselves, regrow their extensions and rebuild lost connections. Semax primarily supports nerve regeneration by increasing both BDNF and NGF – the two main neurotrophic factors driving neuron survival, axon growth (regrowth of the long extensions by which nerve cells communicate) and synaptic reconnection after injury.
In a spinal cord injury model, Semax promoted functional recovery by interacting with μ-opioid receptors – a type of receptor more commonly known for its role in pain processing – and through a cellular mechanism involving the protein USP18, which regulates how damaged cellular components are degraded and cleared. It also reduced the permeability of lysosomal membranes – the protective walls of the cell's internal waste-processing compartments, the rupture of which causes further damage. Functional outcomes in this model included improved motor function, normalised gait analysis, and better performance in balance and coordination tests [12].
At a cellular level, Semax increased the proliferative activity – that is, the rate of cell division and multiplication – of neuroglial cells, vascular endothelial cells, and progenitor cells in the periventricular zone in both normal and stroke-affected rat brains [13]. These effects directly support the tissue repair and regeneration processes needed after nervous system injury.
In clinical studies of optic nerve diseases – conditions affecting the nerve that transmits visual signals from the eye to the brain – Semax induced significant improvements in visual acuity, visual field expansion, ocular electrical sensitivity, and the speed of electrical signal conduction along the optic nerve in patients with vascular, toxic-allergic, and inflammatory optic nerve disorders [14]. These findings align with neurotrophic support and partial regeneration of optic nerve fibres. However, these clinical trial designs did not allow for definitive conclusions regarding which specific neurotrophic mechanisms were responsible, and controlled studies with direct neurotrophin measurements would be needed to more strongly establish this link in humans.
Does Semax promote neuroplasticity?
Semax promotes neuroplasticity through several converging mechanisms, including by increasing BDNF and TrkB signalling, enhancing glutamatergic synaptic activity, modulating short-term synaptic plasticity, and activating gene-level pathways associated with neurotransmission. Neuroplasticity is the brain's ability to reorganise – strengthening useful connections between nerve cells, weakening unused ones, and creating entirely new ones in response to learning, experience, or injury.
The hippocampal BDNF/TrkB pathway activation by Semax is particularly important here. BDNF-TrkB signalling is considered a master regulator of activity-dependent synaptic plasticity – meaning it controls how effectively synapses strengthen in response to repeated activity. This process, known as long-term potentiation, is the cellular mechanism that most closely underlies learning and memory formation.
In hippocampal slices – thin sections of living hippocampal tissue maintained in the laboratory – Semax at a concentration of 1 micromole significantly increased the frequency of spontaneous intracellular calcium fluctuations in the pyramidal cells of the CA1 field [15]. Calcium fluctuations within nerve cells are a direct indicator of cellular activity and synaptic communication. An increase in these fluctuations is consistent with increased excitability of the hippocampal network, which underpins plasticity processes.
At the level of individual synapses – the points of connection between nerve cells – long-term culture of nerve cells with Semax at concentrations of 10 and 100 micromoles increased the frequency of spontaneous glutamatergic postsynaptic currents to 71.7% and 93.9% above control levels [16]. Semax also increased the quantum of synaptic vesicle release – meaning that each nerve signal triggered the release of a greater amount of neurotransmitter – and modified the parameters of short-term plasticity in a manner consistent with an improvement in the efficiency of presynaptic glutamate release [16]. These electrophysiological findings indicate that Semax directly enhances the efficacy of excitatory synaptic transmission, which constitutes the cellular basis for the brain’s strengthening of connections during learning.
In healthy volunteers, brain imaging using resting-state functional MRI – a technique that measures brain activity by detecting changes in blood flow associated with neural cell activity – showed that Semax induced a greater volume of activity in a specific part of the default mode network called the rostral component, located in the medial prefrontal cortex, compared to placebo at both 5 and 20 minutes post-administration [17]. The default mode network is a group of brain regions that work together during internally directed thought, self-reflection, and working memory. This finding provides direct neuroimaging evidence from human studies of altered brain network organisation consistent with modified synaptic and circuit-level plasticity.
Does Semax promote neurogenesis?
Semax promotes neurogenesis, with evidence from cell proliferation studies and neonatal administration models indicating its capacity to enhance the production of new neurons and support neuronal progenitor cell activity. Neurogenesis is the process by which the brain produces entirely new nerve cells. Although it was long believed that adults could not generate new neurons, research has demonstrated that new nerve cells can be generated in at least two specific areas of the adult brain: the subventricular zone and the dentate gyrus of the hippocampus.
In rat stroke models, Semax increased cell proliferation activity in the periventricular zone, as confirmed by histological analysis – microscopic examination of tissue samples. It also increased the proliferation of neuroglial cells and blood vessel endothelial cells, supporting a broader regenerative environment in the damaged brain [13].
In studies on newborn rats, Semax injections administered on days 7–11 post-birth enhanced neurogenesis in the dentate gyrus of the hippocampus. The effects on seizure susceptibility – specifically, the kind of seizures induced by loud sounds – observed in adult animals were attributed, at least in part, to this enhancement of early hippocampal neurogenesis [18]. Direct examination of cellular proliferation confirmed that neonatal Semax injection induced measurable changes in cellular proliferation within the dentate gyrus region of the hippocampus, with the magnitude of the effect being dependent on the animal's genetic background [19].
These neurogenesis-promoting effects are mechanistically consistent with Semax-induced BDNF increase, as BDNF is one of the most potent known promoters of adult hippocampal neurogenesis. It acts by activating TrkB receptors on neuronal stem cells in the subgranular zone – the layer just beneath the dentate gyrus – driving their proliferation, differentiation into mature neurons and long-term survival.
In studies of catecholaminergic neurons in young mice – neurons that produce dopamine and norepinephrine – administration of Semax modulated the total number of these neurons in the adult midbrain. This indicates that early exposure to Semax may permanently alter the neuronal composition of specific brain areas by influencing developmental neurogenesis and neuronal survival [20].
It is worth noting that the majority of evidence regarding neurogenesis for Semax comes from neonatal or injury models, rather than studies of neurogenesis in the healthy adult brain. Whether Semax significantly enhances hippocampal neurogenesis in healthy adult humans under normal physiological conditions has not yet been directly investigated.
Semax influence on learning and memory at the cellular level.
At the cellular level, Semax enhances learning and memory through several convergent mechanisms: increasing hippocampal BDNF and TrkB signalling, improving cholinergic neuron function and survival, enhancing glutamatergic synaptic transmission, modulating intracellular signalling pathways, and activating gene-level programmes related to neurotransmission.
A direct link between Semax-induced changes in BDNF and cognitive outcomes has been established, by demonstrating that animals with the highest increases in BDNF and TrkB mRNA in the hippocampus following Semax administration also exhibited the greatest improvement in a conditioned avoidance learning task [2]. In a passive avoidance task – another standard test of memory consolidation – intranasal Semax induced a stronger improvement in learning than intraperitoneal injection at equivalent doses, which is consistent with the nasal route delivering higher concentrations directly to the brain and driving a greater increase in hippocampal BDNF [21].
At the level of intracellular signal transduction – the chain of molecular events occurring within cells – Semax altered the activity of genes involved in signal transduction pathways in the rat hippocampus, affecting multiple kinase cascades – chains of enzymes that transmit signals within cells – which regulate synaptic strength and memory consolidation [22].
In a model of cortical–prefrontal stroke, chronic intranasal administration of Semax at a dose of 250 micrograms per kilogram of body weight per day for six days following an experimentally induced stroke led to the complete restoration of spatial learning ability in the Morris water maze—a standard test where animals must use environmental cues to locate a submerged platform in a pool of water. Importantly, this anti-amnesic effect—the reversal of memory loss—persisted long after the treatment course had ended [23]. This suggests that Semax induced lasting neuroplastic remodelling—long-term structural and functional changes in the brain—rather than merely providing short-term cognitive support.
A protein expression profiling study – measuring the levels of many proteins simultaneously – in a rat stroke model demonstrated that Semax increased CREB activity in subcortical structures, including the stroke-affected area [24]. CREB is a transcription factor – a protein that turns genes on and off – and is considered the molecular switch most directly responsible for translating synaptic activity into long-term memory storage via changes in gene expression. Simultaneously, Semax reduced the activity of MMP-9, c-Fos, and active JNK – proteins associated with inflammation and cellular stress responses [24]. This combination of CREB activation along with inflammatory suppression represents a molecular pattern strongly consistent with enhanced memory consolidation and neuroprotective plasticity.
Does Semax have the potential to improve intelligence or increase IQ?
No published studies have assessed the effects of Semax on IQ scores or general intelligence measures in healthy individuals. Claims of improved intelligence would go beyond what current scientific evidence supports.
What the research actually shows is an improvement by Semax in specific cognitive areas – including learning speed, memory consolidation, selective attention, and working memory – in animal models and in humans with neurological diseases such as ischaemic stroke and cerebrovascular insufficiency.
In healthy volunteers, Semax improved memory and attention under cognitive load. A review of a 15-year development period noted improvements in working memory and selective attention after intranasal Semax in both healthy individuals under extreme stress or cognitive load conditions, and in clinical patient populations [25]. Resting-state brain imaging changes observed in healthy individuals suggest that Semax modulates functional connectivity – how well different brain areas communicate with each other – in networks relevant to cognitive function [17]. Observed changes in the default mode network are consistent with effects on internally directed thought, self-referential processing, and working memory.
Whether these measurable improvements in specific cognitive domains translate into significant changes in general cognitive abilities or intelligence in healthy individuals with normal baseline function remains unknown as it has not been formally investigated. Available animal evidence suggests that the cognitive benefits of Semax are most pronounced under conditions of cognitive challenge, stress, injury, or initial deficit – rather than through mere enhancement of already optimal cognitive performance. This is consistent with BDNF data showing preferential increases in cognitively impaired mice [10]. The robust scientific answer is: Semax exhibits true and well-documented effects on learning, memory and attention in preclinical models and in patients with neurological diseases – whereas whether it significantly enhances cognitive outcomes in healthy humans with normal baseline function requires rigorous, placebo-controlled clinical trials, which have not yet been published.
Disclaimer
This article is for educational and informational-scientific purposes only and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or a claim regarding the efficacy of Semax in treating any condition. Semax remains a research compound in most countries, including the United States and most European countries, and is not approved by the Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. It is approved and used clinically in Russia and some Eastern European countries. Most of the evidence presented in this article comes from preclinical animal studies and a limited number of human clinical trials. Additional, well-designed clinical trials are necessary to more accurately establish the safety, efficacy, mechanisms of action, and long-term effects of Semax in humans.
References
[1] Shadrina, M. I., Dolotov, O. V., Grivennikov, I. A., Slominsky, P. A., Andreeva, L. A., Inozemtseva, L. S., Limborska, S. A., & Myasoedov, N. F. (2001). Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neuroscience Letters, 308(2), 115–118. https://doi.org/10.1016/s0304-3940(01)01994-2
[2] Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Yu., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108
[3] Shadrina, M., Kolomin, T., Agapova, T., Agniullin, Y., Shram, S., Slominsky, P., Lymborska, S., & Myasoedov, N. (2010). Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Journal of Molecular Neuroscience, 41(1), 30–35. https://doi.org/10.1007/s12031-009-9270-z
Agapova, T. Yu., Agniullin, Ya. V., Silachev, D. N., Shadrina, M. I., Slominsky, P. A., Shram, S. I., Limborskaya, S. A., & Miasoedov, N. F. (2008). Effect of semax on the temporary dynamics of brain-derived neurotrophic factor and nerve growth factor gene expression in the rat hippocampus and frontal cortex. Molecular Genetics, Microbiology and Virology, (3), 28–32. PMID: 18756821
[5] Dmitrieva, V.G., Povarova, O.V., Skvortsova, V.I., Limborska, S.A., Myasoedov, N.F., & Dergunova, L.V. (2010). Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischaemia. Cellular and Molecular Neurobiology, 30(1), 71–79. https://doi.org/10.1007/s10571-009-9432-0
[6] Radchenko, A. I., Kuzubova, E. V., Apostol, A. A., Mitkevich, V. A., Andreeva, L. A., Limborska, S. A., Stepenko, Yu. V., Shmigerova, V. S., Solin, A. V., Korokin, M. V., Pokrovskii, M. V., Myasoedov, N. F., & Makarov, A. A. (2025). The potential of the peptide drug Semax and its derivative for correcting pathological impairments in the animal model of Alzheimer’s disease. Acta Naturae, 17(4), 110–120. https://doi.org/10.32607/actanaturae.27808
[7] Kolacheva, A. A., & Ugrumov, M. V. (2021). A mouse model of nigrostriatal dopaminergic axonal degeneration as a tool for testing neuroprotectors. Acta Naturae, 13(3), 110–113. https://doi.org/10.32607/actanaturae.11433
[8] Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of semax in the treatment of patients at different stages of ischaemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
[9] Gusev, E. I., Skvortsova, V. I., Miasoedov, N. F., Nezavibat’ko, V. N., Zhuravleva, E. Yu., & Vanichkin, A. V. (1997). Effectiveness of semax in the acute period of hemispheric ischaemic stroke (a clinical and electrophysiological study). Journal of Neurology and Psychiatry named after S.S. Korsakov, 97(6), 26–34. PMID: 11517472
Firstova, Yu. Yu., Dolotov, O. V., Kondrakhin, E. A., Dubynina, E. V., Grivennikov, I. A., & Kovalev, G. I. (2009). Effects of nootropic drugs on hippocampal and cortical BDNF levels in mice with different exploratory behaviour efficacy. Experimental and Clinical Pharmacology, 72(6), 3–6. PMID: 20095391
[11] Dolotov, O. V., Karpenko, E. A., Seredenina, T. S., Inozemtseva, L. S., Levitskaya, N. G., Zolotarev, Yu. A., Kamensky, A. A., Grivennikov, I. A., Engele, J., & Myasoedov, N. F. (2006). Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry, 97(Suppl 1), 82–86. https://doi.org/10.1111/j.1471-4159.2006.03658.x
[12] Liu, R., Chen, Y., Huang, H., Li, X., Lv, J., Jiang, L., Jiang, H., Wu, C., Chen, W., Xu, H., Zhu, Z., Cai, H., Xiao, J., Yin, L., & Ni, W. (2025). Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. British Journal of Pharmacology, 182(22), 5489–5516. https://doi.org/10.1111/bph.70122
[13] Stavchansky, V. V., Yuzhakov, V. V., Botsina, A. Yu., Skvortsova, V. I., Bondurko, L. N., Tsyganova, M. G., Limborska, S. A., Myasoedov, N. F., & Dergunova, L. V. (2011). The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischaemia: A pilot study. Journal of Molecular Neuroscience, 45(2), 177–185. https://doi.org/10.1007/s12031-010-9421-2
[14] Polunin, G. S., Nurieva, S. M., Baiandin, D. L., Sheremet, N. L., & Andreeva, L. A. (2000). Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease. Journal of Ophthalmology, 116(1), 15–18. PMID: 10741256
[15] Kolbaev, S. N., Sharonova, I. N., & Skrebitsky, V. G. (2025). The effect of peptide Semax, an ACTH(4-10) analogue, on intracellular calcium dynamics in rat brain neurons. Bulletin of Experimental Biology and Medicine, 179(4), 416–420. https://doi.org/10.1007/s10517-025-06501-z
Shypshyna, M. S., Veselovsky, N. S., Myasoedov, N. F., Shram, S. I., & Fedulova, S. A. (2015). Effect of peptide Semax on synaptic activity and short-term plasticity of glutamatergic synapses of co-cultured dorsal root ganglion and dorsal horn neurons. Physiological Journal, 61(4), 48–55. https://doi.org/10.15407/fz61.04.048
[17] Lebedeva, I. S., Panikratova, Ya. R., Sokolov, O. Yu., Kupriyanov, D. A., Rumshiskaya, A. D., Kost, N. V., & Myasoedov, N. F. (2018). Effects of Semax on the default mode network of the brain. Bulletin of Experimental Biology and Medicine, 165(5), 653–656. https://doi.org/10.1007/s10517-018-4234-3
[18] Timoshenko, T. V., Perepelkina, O. V., Markina, N. V., Revischin, A. V., Pavlova, G. V., Poletaeva, I. I., & Sukhih, G. T. (2009). Audiogenic epilepsy in mice with different genotypes after neonatal treatments enhancing neurogenesis in dentate gyrus. Bulletin of Experimental Biology and Medicine, 147(4), 458–461. https://doi.org/10.1007/s10517-009-0558-3
[19] Timoshenko, T. V., Poletaeva, I. I., Pavlova, G. V., & Revishchin, A. V. (2009). Effect of neonatal injections of the neuropeptide Semax on cell proliferation in hippocampal dentate area in rats of two genotypes. Doklady Biological Sciences, 424, 78–80. https://doi.org/10.1134/s0012496609010232
Boyarshinova, O. S., Revishchin, A. V., Poletaeva, I. I., & Korochkin, L. I. (2004). Neonatal administration of ACTH4-10 and its analog Semax to young laboratory mice modulates the number of catecholaminergic neurons in adult animal diencephalon. Doklady Biological Sciences, 396, 181–183. https://doi.org/10.1023/b:dobs.0000033270.71306.3d
[21] Manchenko, D. M., Glazova, N. Yu., Levitskaia, N. G., Andreeva, L. A., Kamenskiĭ, A. A., & Miasoedov, N. F. (2010). Nootropic and analgesic effects of Semax following different routes of administration. I.M. Sechenov Russian Journal of Physiology, 96(10), 1014–1023. PMID: 21268834
Agapova, T. Yu., Agniullin, Ya. V., Silachev, D. N., Shadrina, M. I., Slominsky, P. A., Shram, S. I., Limborskaya, S. A., & Myasoedov, N. F. (2007). Expression changes caused by the peptide semax in the intracellular signal pathway genes in rat hippocampus. Doklady Biochemistry and Biophysics, 417, 334–336. https://doi.org/10.1134/s1607672907060129
[23] Silachev, D. N., Shram, S. I., Shakova, F. M., Romanova, G. A., & Myasoedov, N. F. (2009). Formation of spatial memory in rats with ischaemic lesions to the prefrontal cortex; effects of a synthetic analogue of ACTH(4-7). Neuroscience and Behavioral Physiology, 39(8), 749–756. https://doi.org/10.1007/s11055-009-9197-4
[24] Sudarkina, O. Yu., Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Valieva, L. V., Remizova, J. A., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2021). Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischaemia-reperfusion. International Journal of Molecular Sciences, 22(12), 6179. https://doi.org/10.3390/ijms22126179
[25] Ashmarin, I. P., Nezavibat’ko, V. N., Miasoedov, N. F., Kamenskiĭ, A. A., Grivennikov, I. A., Ponomareva-Stepnaia, M. A., Andreeva, L. A., Kaplan, A. Ia., Koshelev, V. B., & Riasina, T. V. (1997). A nootropic adrenocorticotropin analogue 4-10-Semax (15 years of its design and study). Journal of Higher Nervous Activity named after I. P. Pavlov, 47(2), 420–430. PMID: 9173745